Welcome to our dedicated page for Biocorrx news (Ticker: BICX), a resource for investors and traders seeking the latest updates and insights on Biocorrx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biocorrx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biocorrx's position in the market.
BioCorRx (OTCQB: BICX) has enrolled the last subject in its Phase I clinical trial for BICX104, a biodegradable naltrexone pellet aimed at treating opioid use disorder (OUD). The trial, led by Dr. Joel M. Neutel, will evaluate the safety and pharmacokinetics of BICX104 compared to the monthly injection Vivitrol. Interim data is expected by year-end, with plans to add more subjects for FDA-required clinical characterization, targeting potential marketing approval in 2023. The study is conducted in collaboration with the National Institute on Drug Abuse.
BioCorRx Inc. (BICX) announced that Lourdes Felix, CEO and Director, will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The conference will be held at the Lotte New York Palace Hotel and will include both in-person and virtual attendance. Attendees can access the presentation on-demand starting September 12 at 7:00 AM ET. BioCorRx focuses on innovative treatment programs for substance abuse and related disorders, including its proprietary programs like Beat Addiction Recovery and UnCraveRx®.
BioCorRx Inc. (BICX) reported a significant milestone in its business update, having dosed its first subject in the Phase I clinical trial of BICX104, a biodegradable naltrexone pellet aimed at treating opioid use disorder (OUD). Collaborating with 2B3D, the company is also piloting a unique PTSD and addiction treatment program for veterans utilizing virtual reality technology. The FDA has accepted the 505(b)(2) abbreviated pathway for BICX104, which may also seek dual indication for OUD and Alcohol Use Disorder (AUD). The Q2 2022 report is now available on their website.
BioCorRx Inc. (OTCQB: BICX) announced that Brady Granier, its President and Director, will present at the Benzinga All Access event on July 15, 2022, at 10:40 A.M. Eastern Time. This live event will focus on the company's innovative treatment programs for substance abuse disorders and related issues. Viewers can watch the presentation live on the company's YouTube channel, with an archived version available on their investor relations website. BioCorRx offers unique addiction solutions, including Cognitive Behavioral Therapy and medication-assisted treatment for weight loss.
BioCorRx announced the successful dosing of the first subject in its Phase I clinical trial for BICX104, a biodegradable naltrexone pellet aimed at treating opioid use disorder (OUD). This trial marks a significant milestone in the company's efforts to address the growing opioid crisis, which saw over 107,000 overdose deaths in 2021. The study, led by Dr. Joel M. Neutel, will evaluate the safety and pharmacokinetics of BICX104 compared to traditional naltrexone injections. BioCorRx is collaborating with the National Institute on Drug Abuse and aims for dual indications for OUD and Alcohol Use Disorder.
BioCorRx Inc. (OTCQB: BICX) announced that Executive VP Tom Welch appeared on LiveNOW from FOX to discuss a pilot program in collaboration with 2B3D. This program focuses on PTSD and addiction treatment solutions for veterans using metaverse technology. BioCorRx provides innovative addiction treatment programs, including Beat Addiction Recovery and the UnCraveRx® Weight Loss Program, along with its clinical stage drug development subsidiary targeting FDA approval for BICX104, an implantable naltrexone pellet.
BioCorRx Inc. (OTCQB: BICX) announced its participation at the LD Micro Invitational XII from June 7-9, 2022. CEO Lourdes Felix and President Brady Granier will present on June 7 at 11:30 AM PT. The presentation will be available via live webcast. BioCorRx focuses on innovative treatment programs for substance abuse and related disorders, including Beat Addiction Recovery and UnCraveRx® for weight loss, featuring cognitive therapy and medication support. The company is also working on BICX104, an implantable naltrexone pellet for treating alcohol and opioid use disorders.
BioCorRx (OTCQB: BICX) has announced a collaboration with 2B3D to develop a treatment program targeting veterans suffering from PTSD and substance use disorders. This initiative integrates BioCorRx's Medication-Assisted Treatment (MAT) program with 2B3D's virtual reality technology to enhance care for at-risk groups, particularly veterans. The collaboration aims to utilize advanced therapeutic approaches to address the dual challenges of PTSD and addiction. Pilot results will guide the expansion of this offering to other demographics.
BioCorRx Inc. (BICX) announced significant advancements in its first quarter of 2022, including the initiation of a clinical trial for BICX104, a biodegradable naltrexone pellet aimed at treating opioid use disorder. The recruitment for this Phase 1 study is a critical milestone. Additionally, the company reported a revenue increase due to a higher patient count in licensed clinics and growing participation in its UnCraveRx™ Weight Loss Management Program. Operating expenses were reduced by nearly 30%, showcasing effective cost management.
BioCorRx Inc. (OTCQB: BICX) has initiated the recruiting and enrollment process for its first-in-human clinical trial of BICX104, a biodegradable naltrexone pellet aimed at treating opioid use disorder (OUD). This Phase 1, open-label study will assess the pharmacokinetics and safety of BICX104 against a marketed naltrexone injection. The trial will be conducted at the Orange County Research Center, led by Dr. Joel M. Neutel. The company enjoys active IND status and FDA acceptance for a 505(b)(2) pathway, potentially allowing for dual indication for OUD and Alcohol Use Disorder (AUD).